Company intelligence
Averin Capital
Identifying and accelerating high performance healthcare companies
About Averin Capital
This is the biology century. Software changed the world over the last 30 years. Technology and biology will converge over the next 30 to have an even larger impact. We focus on four key verticals: 1) Artificial Intelligence: therapeutic development platforms, diagnostic and decision support, workflow and insurance, and predictive analytics. 2) Longevity: early screening and intervention, preventative care, remote patient monitoring and care, and integrated care platforms. 3) Data-driven care: value-based care, real world data / evidence, payment integrity, and sustainable healthcare models. 4) Deep technology: synthetic biology, nanotechnology, personalized medicine, and genomics.
Verified activity
Signals from Averin Capital
4 published signals
Presence & Recognition
Averin Capital hosted an Averin Insights Fireside Chat featuring David Berry and Thierry Bernard, CEO of QIAGEN, discussing the future of diagnostics.
Reported by Averin Capital
Presence & Recognition
Averin Capital featured Thierry BERNARD, the CEO of QIAGEN, discussing the imbalance between diagnostics and clinician decisions in the latest installment of Insights from Averin Capital.
Reported by Eric Berry
Presence & Recognition
Averin Capital employee David Berry and Thierry Bernard of QIAGEN discussed the future of diagnostics and the potential for early detection of chronic diseases.
Reported by David Berry
Research & Knowledge
Averin Capital featured Thierry Bernard and his partner David Berry in an Averin Insights fireside chat discussing the future of diagnostics and the challenges hospitals face.
Reported by Jeffrey Low, MD